EvaluatePharma Orphan Drug Report 2015

Worldwide orphan drug sales forecast to total $178bn

Orphan Drug Report 2015 - Report Cover

With 2020 worldwide sales forecast at $178 billion, the orphan drug market is expected to grow by 11.7% per year (CAGR 2015 to 2020), nearly doubling the yearly growth of the overall prescription market.

Moreover, worldwide orphan drug sales will account for 20.2% of worldwide prescription sales by 2020 (excluding generics) according to the EvaluatePharma Orphan Drug Report 2015.

Key highlights

  • Median cost per patient is 13.8 times higher for orphan drugs compared to non-orphan.

  • Worldwide orphan drug sales are forecast to total $178bn (CAGR 2015 to 2020: +11.7%); nearly double the overall prescription market growth.

  • Celgene overtakes Novartis and climbs to the number one position in orphan drug sales by 2020 thanks to top selling Revlimid.

  • Phase III orphan drug development costs are half that of non-orphan but Phase III drug development is no quicker for orphan than non-orphan drugs.

  • Return on investment of Phase III/ filed orphan drugs is 1.14 times greater than the ROI for non-orphan drugs.

  • 2014 was a record year for orphan drug designations with the FDA awarding 291, Europe awarding 201 and Japan awarding 32 designations.

  • Opdivo ranks as the most promising new orphan drug approved in the US in 2014 while Obeticholic Acid (Intercept Pharmaceuticals) ranks as the most valuable R&D product.



Download Report